POZ Community Forums

Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: a2z on October 29, 2007, 02:46:16 am

Title: No new PIs?
Post by: a2z on October 29, 2007, 02:46:16 am
I was looking at the drug chart tonight, and noticed there are several new drugs in the works, but none in the PI class.  Is there a reason for this that anyone knows of?
Title: Re: No new PIs?
Post by: ronaldinho on October 29, 2007, 07:44:15 am
Darunavir ( = prezista), from Tibotec, is the most recent PI approved.

http://hivandhepatitis.com/recent/2007/102607_d.html

The only other that i could found to to be in development is PPL-100 from Merck. But if you look in the menu of ARVs in the link above, PIs and NRTIs are the classes with the most variety of options.
Title: Re: No new PIs?
Post by: ronaldinho on October 29, 2007, 07:52:48 am
wrong message
Title: Re: No new PIs?
Post by: a2z on November 05, 2007, 02:32:09 am
Well I found part of my answer here http://img.thebody.com/tag/pipeline.pdf

Is this just because PIs are "old news?" and the rest is more exciting (and potentially more profitable?)
Title: Re: No new PIs?
Post by: Miss Philicia on November 05, 2007, 04:21:30 am
Aside from Prezista which was mentioned (and which came out a year ago) Aptivus is also new (in the last 2 years) -- that's 10 PI's now so I'm not sure why they would want to glut the market.

However, these PI's are slightly different as they're better for people with PI resistance issues.  As well, all of the new HIV meds that are non-PI like Isentress, Selzentry and Etravirine are also aimed at patients with multiple resistance issues.

I'm not sure why you want what seems "more of the same" -- the longer we all live the more resistance issues all of us will face, so these other class drugs are needed.  Plus entire new classes, like Isentress is as an integrase inhibitor, will eventually (I assume) be used as more of a first line treatment once it's studied more, and could very well prove more effective and tolerable in terms of side effects than what we have now.
Title: Re: No new PIs?
Post by: MitchMiller on November 05, 2007, 10:55:09 pm
Pl-100 is a new PI that's looking potent.  I forget who's developing it but here's a recent blurb on it:
http://aac.asm.org/cgi/content/abstract/51/11/4036 
Sorry... I see PL-100 is the same as PPL-100 that has already been mentioned in the thread.  Here's the original developer of that drug (they licensed it to Merck)....
http://www.ambrilia.com/en/products/hiv-aids-ppl-100.php
Title: Re: No new PIs?
Post by: a2z on November 06, 2007, 12:03:07 am
I'm not sure why you want what seems "more of the same" -- the longer we all live the more resistance issues all of us will face, so these other class drugs are needed.  Plus entire new classes, like Isentress is as an integrase inhibitor, will eventually (I assume) be used as more of a first line treatment once it's studied more, and could very well prove more effective and tolerable in terms of side effects than what we have now.

It was not "wanting more of the same" -- it was curiousity as to why research seems to have stopped on this one type.  I'm still learning and it seemed like a logical question I couldn't really find the answer for myself.

But I think you gave a pretty thorough hypothesis as to why and I appreciate it.
Title: Re: No new PIs?
Post by: ronaldinho on November 30, 2007, 01:40:25 pm
A good overview on antiretrovirals in development can be found  in the pdf document (pages 45 to 78) downloadable in the link below:

http://www.hivmedicine.com/hivmedicine2007.pdf